(1)A 0.5 mg intravenous dose of scopolamine did not alter the global glucose metabolic rates of young and older normals. In the younger normals, studied while performing a task requiring sustained attention, the most prominent effects were in those regions of the brain hypothesized to be part of the brain's attention network, e.g. the thalamus and cingulate cortex. In the older subjects, at rest, thalamic affects were not apparent, but decreases in the frontal cortex were observed. Neither group showed changes consistent with changes seen in Alzheimer's Disease. Thus, lesions of the muscarinic cholinergic system are not likely to contribute to the hypometabolic changes seen in Alzheimer's Disease, and that the sensitivity of frontal cortex functional activity to muscarinic blockade may be responsible for the increased sensitivity of older subjects to the memory impairing affects of scopolamine. (2)The dose and time dependency of the affects on regional blood flow in normals of the administration of the high affinity central benzodiazepine receptor agonist was evaluated. Lorazepam decreased blood flow to a large number of brain regions including the cingulate, thalamus and corpus striatum in a dose dependent manner which was reversed by the benzodiazepine antagonist flumazenil. Having been validated, regional blood flow responses can now be used to evaluate benzodiazepine receptor sensitivity in the variety of neuropsychiatric disorders in which this pathway has been implicated. (3) We examined regional brain activities in dyslexia during a tonal memory task. We found diminished activation in right frontotemporal regions in the presence of normal left mid to anterior temporal cortex activation. These results support hypothesized underlying deficits in rapid temporal processing and probable involvement of both right and left temporal cortex in severe dyslexia.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Intramural Research (Z01)
Project #
1Z01MH000507-13
Application #
5203665
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
1995
Total Cost
Indirect Cost
Name
U.S. National Institute of Mental Health
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Cohen, Robert M; Szczepanik, Joanna; McManus, Michael et al. (2006) Hippocampal atrophy in the healthy is initially linear and independent of age. Neurobiol Aging 27:1385-94
Cannon-Spoor, H Eleanor; Levy, James A; Zubenko, George S et al. (2005) Effects of previous major depressive illness on cognition in Alzheimer disease patients. Am J Geriatr Psychiatry 13:312-8
Toyama, Hiroshi; Ye, Daniel; Ichise, Masanori et al. (2005) PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging 32:593-600
Levy, James A; Bergeson, Judy; Putnam, Karen et al. (2004) Context-specific memory and apolipoprotein E (ApoE) epsilon 4: cognitive evidence from the NIMH prospective study of risk for Alzheimer's disease. J Int Neuropsychol Soc 10:362-70
Sunderland, Trey; Mirza, Nadeem; Putnam, Karen T et al. (2004) Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 56:670-6
Podruchny, Teresa A; Connolly, Catherine; Bokde, Arun et al. (2003) In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse 48:39-44
Cohen, Robert M; Podruchny, Teresa A; Bokde, Arun L W et al. (2003) Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon4 allele. Synapse 49:150-6
Doudet, D J; Holden, J E; Jivan, S et al. (2000) In vivo PET studies of the dopamine D2 receptors in rhesus monkeys with long-term MPTP-induced parkinsonism. Synapse 38:105-13
Elkashef, A M; Doudet, D; Bryant, T et al. (2000) 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 100:11-Jan
Wyatt, R J; Henter, I D; Bartko, J J (1999) The long-term effects of placebo in patients with chronic schizophrenia. Biol Psychiatry 46:1092-105

Showing the most recent 10 out of 11 publications